Fidelity International’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-68,816
Closed -$10.3M 875
2021
Q4
$10.3M Sell
68,816
-53,390
-44% -$8.18M 0.01% 533
2021
Q3
$17.8M Sell
122,206
-80,403
-40% -$13.8M 0.02% 456
2021
Q2
$39.7M Sell
202,609
-56,219
-22% -$10.2M 0.04% 345
2021
Q1
$46.8M Sell
258,828
-2,233
-0.9% -$386K 0.05% 297
2020
Q4
$37M Sell
261,061
-2,218,394
-89% -$322M 0.05% 339
2020
Q3
$309M Buy
+2,479,455
New +$260M 0.38% 68

Other funds holding TXG

Fidelity International's TXG Position: Q1 2022 in Review

Fidelity International sold out of 10x Genomics (TXG) in Q1 2022, closing a stake of 68,816 shares — an estimated $10.3M sold.

Fidelity International first reported a position in TXG in Q3 2020 and held it in 6 quarters. The position peaked at $309M in Q3 2020. 314 funds tracked by Wall St. Rank hold TXG as of Q1 2022.

  • Fidelity International reported no remaining 10x Genomics position as of Q1 2022 after selling out during the quarter.
  • Fidelity International sold 68,816 10x Genomics shares in Q1 2022, an estimated $10.3M.
  • Fidelity International first reported a position in 10x Genomics in Q3 2020 and held it in 6 quarters.
  • Fidelity International's 10x Genomics position peaked at $309M in Q3 2020.
  • 314 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2022.

Based on Fidelity International's 13F filing for Q1 2022, filed 13 May 2022.